Ungerechts Lab

Guy Ungerechts profile picture

Contact Information

Guy Ungerechts, MD, PhD
613 737 8899 x 75201
gungerechts@ohri.ca

Ottawa Hospital Research Institute
Center for Cancer Therapeutics
501 Smyth Rd. Box 926,
Ottawa, On, K1H 8L6

What We Do

The group of Dr. Guy Ungerechts is investigating methods to destroy cancer cells and stimulate a patient’s own immune system to attack tumours, while leaving healthy tissue unharmed.
He modifies Measles virus derived from a vaccine strain to work as an oncolytic virus by directly killing cancer cells and by providing mechanisms to stimulate the immune system.
Having received a New Investigator grant from the Terry Fox Research Institute and being part of the Canadian Oncolytic Virus Consortium (COVCo), he develops innovative treatments in cooperation with Dr. John Bell, senior scientist at The Ottawa Hospital and COVCo lead investigator.
The team plans to use a modified version of the Measles virus vaccine as an oncolytic “cancer vaccine”, enhancing it with a second virus (Maraba virus) that will act as a booster. This next-generation immunovirotherapy would use two replicating viruses to hopefully maximize tumour destruction. The novel treatment is intended to be moved to clinical trials for advanced-stage cancer patients.
With the goal of further improving tumour specificity and oncolytic efficacy, Dr. Ungerechts is exploring several approaches with a panel of genetically modified Measles viruses for cancer therapy.

Selected Publications

1. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G. CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. Molecular Therapy, accepted 20 August 2014

2. Baertsch MA, Leber, MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jäger D, von Kalle C and Ungerechts G. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Therapy 2014, in press

3. Ketzer P, Kaufmann JK, Engelhardt S, Bossow S, von Kalle C, Hartig JS, Ungerechts G, Nettelbeck DM. Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. PNAS, 2014 Feb 4;111(5):E554-62. doi: 10.1073/pnas.1318563111. PubMed PMID: 24449891

4. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. GM-CSF-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.PMID:23642239

5. Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. J Invest Dermatol. 2013 Apr;133(4):1034-42. doi: 10.1038/jid.2012.459. Epub 2012 Dec 6. PubMed PMID: 23223133

Meet the Ungerechts Lab